Frankfurt - Delayed Quote EUR

Collegium Pharmaceutical, Inc. (354.F)

25.40

+0.20

+(0.79%)

At close: May 28 at 3:42:38 PM GMT+2

Branded Pharmaceuticals Stocks Q1 Results: Benchmarking Corcept (NASDAQ:CORT)

Let’s dig into the relative performance of Corcept (NASDAQ:CORT) and its peers as we unravel the now-completed Q1 branded pharmaceuticals earnings season.

StockStory 6 days ago

CORT

CELG-RT

PFE
Collegium Pharmaceutical's (NASDAQ:COLL) Conservative Accounting Might Explain Soft Earnings

Collegium Pharmaceutical, Inc.'s ( NASDAQ:COLL ) stock was strong despite it releasing a soft earnings report last...

Simply Wall St. 8 days ago

COLL
Collegium to Participate in Upcoming Investor Conferences

STOUGHTON, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that its management will participate in the following investor conferences: Mizuho Neuro & Ophthalmology Summit 2025Panel Presentation: Wednesday, May 21, 2025, at 11:25 a.m. ET Jefferies Global Healthcare ConferencePresentation: Thursday, June 5, 2025, at 1:25 p.m. ET The presentation at Jefferies Global Healthcare Conference will be webcast live and can be accessed from the Investor

GlobeNewswire 9 days ago

COLL
3 Small-Cap Stocks Facing Headwinds

Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside risk because they lack the scale and staying power of their larger competitors.

StockStory 13 days ago

COLL

IACVV
Collegium Announces $25 Million Accelerated Share Repurchase Program

STOUGHTON, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it has entered into an Accelerated Share Repurchase ("ASR") agreement with Jefferies LLC to repurchase $25 million of the Company’s common stock. Collegium will execute the ASR as part of the $150 million share repurchase program authorized by its B

GlobeNewswire 16 days ago

COLL
Collegium Pharmaceutical Inc (COLL) Q1 2025 Earnings Call Highlights: Strong Revenue Growth ...

Collegium Pharmaceutical Inc (COLL) reports impressive revenue and prescription growth, while navigating increased operating expenses and market challenges.

GuruFocus.com 19 days ago

COLL
Collegium Pharmaceutical (NASDAQ:COLL) Exceeds Q1 Expectations

Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) reported Q1 CY2025 results topping the market’s revenue expectations, with sales up 22.7% year on year to $177.8 million. The company expects the full year’s revenue to be around $742.5 million, close to analysts’ estimates. Its non-GAAP profit of $1.49 per share was 2.8% above analysts’ consensus estimates.

StockStory 20 days ago

COLL
Compared to Estimates, Collegium Pharmaceutical (COLL) Q1 Earnings: A Look at Key Metrics

The headline numbers for Collegium Pharmaceutical (COLL) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks 20 days ago

COLL
Collegium Pharmaceutical (COLL) Q1 Earnings and Revenues Surpass Estimates

Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of 4.20% and 3.08%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks 20 days ago

COLL
Collegium Pharmaceutical: Q1 Earnings Snapshot

On a per-share basis, the Stoughton, Massachusetts-based company said it had profit of 7 cents. Earnings, adjusted for one-time gains and costs, were $1.49 per share. The results beat Wall Street expectations.

Associated Press Finance 20 days ago

COLL
Collegium Reports First Quarter 2025 Financial Results and Highlights Recent Company Progress

– Generated Q1’25 Quarterly Net Revenue of $177.8 Million, Up 23% Year-over-Year – – Grew Jornay PM® Prescriptions by 24% Year-over-Year and Reported Quarterly Net Revenue of $28.5 Million; Jornay PM Prescribers Reached an All-Time-High – – Completed Jornay PM Field Force Expansion – – Generated Net Revenue of $149.2 Million from the Pain Portfolio, Up 3% Year-over-Year with All Three Core Products Recording Revenue Growth in the Quarter – – Ended Q1’25 with Cash, Cash Equivalents and Marketable

GlobeNewswire 20 days ago

COLL
Collegium Pharmaceutical (COLL) Q1 Earnings: What To Expect

Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) will be reporting earnings tomorrow after market close. Here’s what to look for.

StockStory 21 days ago

COLL
Collegium Pharmaceutical (COLL) Expected to Beat Earnings Estimates: Should You Buy?

Collegium Pharmaceutical (COLL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks 27 days ago

COLL

ESPR
3 Healthcare Stocks That Concern Us

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the industry’s returns - over the past six months, healthcare stocks have collectively shed 11.7%. This drawdown was worse than the S&P 500’s 5.2% decline.

StockStory 30 days ago

CORT

SEM

COLL
Collegium to Report First Quarter 2025 Financial Results on May 8, 2025

STOUGHTON, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that it will report first quarter 2025 financial results after the market closes on Thursday, May 8, 2025. Following the release of the financials, the Company will host a live conference call and webcast at 4:30 p.m. ET. Conference Call InformationTo access the conference call, please dial (877) 407-8037 (U.S.) or (201) 689-8037 (International) and reference the “Collegium Pharmace

GlobeNewswire last month

COLL
Is Collegium Pharmaceutical (COLL) Stock Undervalued Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks last month

COLL
2 Reasons to Watch COLL and 1 to Stay Cautious

Collegium Pharmaceutical’s stock price has taken a beating over the past six months, shedding 31.6% of its value and falling to $26.01 per share. This might have investors contemplating their next move.

StockStory last month

COLL
Is Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) 30% ROE Better Than Average?

One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...

Simply Wall St. last month

COLL
A Look Back at Branded Pharmaceuticals Stocks’ Q4 Earnings: Collegium Pharmaceutical (NASDAQ:COLL) Vs The Rest Of The Pack

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Collegium Pharmaceutical (NASDAQ:COLL) and the rest of the branded pharmaceuticals stocks fared in Q4.

StockStory last month

COLL

SUPN

ZTS
Collegium to Participate in 24th Annual Needham Virtual Healthcare Conference

STOUGHTON, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that management will participate in a fireside chat at the 24th Annual Needham Healthcare Conference being held virtually from April 7-10, 2025. Details of the event are as follows:Fireside Chat Date and Time: Tuesday, April 8, 2025, at 9:30 a.m. ET The fireside chat will be webcast live and can be accessed from the Investors section of the Company's website: https://ir.collegiumpha

GlobeNewswire last month

COLL

Performance Overview

Return	354.F	S&P 500 (^GSPC)
YTD	-7.97%	+0.12%
1-Year	-18.59%	+10.98%
3-Year	+77.62%	+41.61%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Collegium Pharmaceutical, Inc. (354.F)

Branded Pharmaceuticals Stocks Q1 Results: Benchmarking Corcept (NASDAQ:CORT)

Collegium Pharmaceutical's (NASDAQ:COLL) Conservative Accounting Might Explain Soft Earnings

Collegium to Participate in Upcoming Investor Conferences

3 Small-Cap Stocks Facing Headwinds

Collegium Announces $25 Million Accelerated Share Repurchase Program

Collegium Pharmaceutical Inc (COLL) Q1 2025 Earnings Call Highlights: Strong Revenue Growth ...

Collegium Pharmaceutical (NASDAQ:COLL) Exceeds Q1 Expectations

Compared to Estimates, Collegium Pharmaceutical (COLL) Q1 Earnings: A Look at Key Metrics

Collegium Pharmaceutical (COLL) Q1 Earnings and Revenues Surpass Estimates

Collegium Pharmaceutical: Q1 Earnings Snapshot

Collegium Reports First Quarter 2025 Financial Results and Highlights Recent Company Progress

Collegium Pharmaceutical (COLL) Q1 Earnings: What To Expect

Collegium Pharmaceutical (COLL) Expected to Beat Earnings Estimates: Should You Buy?

3 Healthcare Stocks That Concern Us

Collegium to Report First Quarter 2025 Financial Results on May 8, 2025

Is Collegium Pharmaceutical (COLL) Stock Undervalued Right Now?

2 Reasons to Watch COLL and 1 to Stay Cautious

Is Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) 30% ROE Better Than Average?

A Look Back at Branded Pharmaceuticals Stocks’ Q4 Earnings: Collegium Pharmaceutical (NASDAQ:COLL) Vs The Rest Of The Pack

Collegium to Participate in 24th Annual Needham Virtual Healthcare Conference

Performance Overview